Vida Ventures
Funding rounds backed by Vida Ventures.
- Funding disclosed in full
- $372M
- Median round
- $75M
- Rounds in calculation
- 5
| Company | Round | Market | Investors | Announced | Details |
|---|---|---|---|---|---|
| InduPro Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease | $77MSeries B | BiotechUnited States | |||
| SonoThera Develops ultrasound-mediated nonviral genetic medicines | $125MSeries B | BiotechUnited States | 16 participantsAlexandria Venture InvestmentsARCH Venture PartnersARK InvestCureDuchenne VenturesDuquesne Family OfficeIllumina VenturesJohnson & Johnson Innovation – JJDCLeaps by BayerMedical Excellence CapitalOtsuka PharmaceuticalRA CapitalSymBiosisUCB Ventures SAVertex Ventures HCVida VenturesVivo Capital | ||
| Adcendo Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment | $75MSeries C | BiotechDenmark | |||
| Poplar Therapeutics Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $45MSeries A+ | BiotechUnited States | |||
| Poplar Therapeutics Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $50MSeries A | HealthtechUnited States |